EKF Diagnostics Holdings plc (EKF) Ordinary 1p

- Add to watchlist
- Create an alert
- This stock can be held in a




Business summary
EKF Diagnostics Holdings plc is primarily engaged in designing, developing, manufacturing and selling diagnostic instruments, reagents and ancillary products, as well as central laboratory reagents. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. It operates in Germany, the United States, Russia and the United Kingdom.
Contact details
Important dates
General stock information
- EPIC:
- EKF
- ISIN:
- GB0031509804
- Market cap:
- £159.23 million
- Shares in issue:
- 454.93 million
- Sector:
- Health Care Equipment & Services
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- FTSE AIM 100,FTSE AIM All Share
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.